- Special Report: Syria's Islamists seize control as moderates dither
- Arizona killer who asked for speedy execution found dead in cell
- Actor James Gandolfini, star of 'The Sopranos,' dies in Italy
- UPDATE 2-Storm Barry heads for Mexico Gulf coast oil installations
- New generation of elite universities rises around the globe
Aveo says cancer drug not better than existing therapy
(Reuters) - Aveo Pharmaceuticals Inc said a combination of its experimental drug to treat a type of lung cancer and the standard of care did not significantly improve the response and survival rate in a mid-stage study.
A combination of Aveo's ficlatuzumab and AstraZeneca's anti-cancer drug gefitinib, which is marketed as Iressa, was tested against gefitinib on Asian patients with non-small cell lung cancer.
Preliminary results from a mid-stage study showed that patients on the combination treatment showed a better response rate and higher disease-progression free survival compared with those on gefitinib alone, but the results were not statistically significant, Aveo said in a statement.
Aveo expects to present complete data from the trial at a medical meeting in the second half of this year.
(Reporting by Zeba Siddiqui in Bangalore; Editing by Roshni Menon)
- Tweet this
- Share this
- Digg this